IOPIDINE
LOE Approachingapraclonidine
NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Jul 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
IOPIDINE (apraclonidine) is clinical pharmacology apraclonidine hydrochloride is a relatively selective alpha-2-adrenergic agonist. First approved in 1993.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IOPIDINE (apraclonidine) is a selective alpha-2-adrenergic agonist ophthalmic solution approved in 1993 for reducing elevated intraocular pressure in glaucoma patients. It works by reducing aqueous humor flow via alpha-adrenergic stimulation, with onset within one hour and maximum effect at three hours. The drug is indicated for glaucoma patients on maximally tolerated medical therapy who require additional IOP reduction before or instead of laser or surgical intervention.
LOE Approaching
Product is in late-stage commercial maturity with LOE approaching; brand team size likely stable or contracting as exclusivity winds down.
Mechanism of Action
CLINICAL PHARMACOLOGY Apraclonidine hydrochloride is a relatively selective alpha-2-adrenergic agonist. When instilled in the eye, apraclonidine ophthalmic solution 0.5%, has the action of reducing elevated, as well as normal, intraocular pressure (IOP), whether or not accompanied by glaucoma.…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.